<DOC>
	<DOCNO>NCT00310856</DOCNO>
	<brief_summary>To assess immunogenicity Novartis ( formerly Chiron ) Meningococcal ACWY conjugate vaccine ( MenACWY ) administer two-dose schedule 6 12 month age .</brief_summary>
	<brief_title>Immunogenicity Safety MenACWY Infants ( 6 &amp; 12 Months )</brief_title>
	<detailed_description />
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Meningitis , Meningococcal</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion criterion Groups I ( MenACWYCRM_612 M ) II ( MenACWYCRM_12 M ) Subjects eligible enrollment study healthy infant : 1. 6 month old born fullterm pregnancy estimate gestational age 37 week great birth weight 2.5 kg great ; 2. previously receive two dos PC7 DTaPHibIPV vaccine ; 3. parent/legal guardian give write informed consent , nature study explain ; 4. available visit schedule study ; 5. good health determine medical history , physical examination , clinical judgment investigator . Inclusion criterion Group III ( MenCCRM_12 M_MenACWYCRM_18 M ) Subjects eligible enrollment study healthy infant : 1. 12 month old ; 2. previously receive three dos DTaPHibIPV ( Pentacel ) vaccine ; 3. parent/legal guardian give write informed consent , nature study explain ; 4. available visit schedule study ; 5. good health determine medical history , physical examination , clinical judgment investigator . Exclusion criterion : Subjects include study : 1. parents/legal guardian unwilling unable give write informed consent participate study ; 2. previously receive meningococcal vaccine ; 3. previously ascertain suspected disease cause Neisseria meningitidis ( N meningitidis ) ; 4. history anaphylactic shock , asthma , urticaria , allergic reaction previous vaccination know hypersensitivity vaccine component ; 5. experience significant acute chronic infection within previous 7 day experience fever ( 38.0ºC great ) within previous 3 day ; 6. present suspect serious acute disease ( e.g. , leukemia , lymphoma ) , chronic disease ( e.g. , sign cardiac failure , renal failure , severe malnutrition , insulindependent diabetes ) , progressive neurological disease , genetic anomaly/known cytogenic disorder ( e.g. , Down 's syndrome ) , diagnose cardiac defect abnormality hemodynamic significance ( e.g. , ventricular septal defect , patent ductus arteriosus , atrial septal defect ) ; 7. know suspect autoimmune disease impairment /alteration immune function result use ( example ) : immunosuppressive therapy since birth ; immunostimulants since birth ; systemic corticosteroid administer 5 day daily dose great 1 mg/kg/day prednisone equivalent 5 day less previous 30 day ; 8. suspect know HIV infection HIVrelated disease ; 9. receive parenteral immunoglobulin preparation , blood product , and/or plasma derivative within past 90 day expect receive full length study ; 10. know bleeding diathesis , condition may associate prolonged bleeding time ; 11. history seizure disorder : febrile seizure ; seizure disorder ; 12. take systemic antibiotic ( either oral parenteral ) within previous 14 day ( EXCEPTION : subject receive oral parenteral βlactam antibiotic [ e.g . : penicillin , amoxicillin , ceftriaxone , cefuroxime cephalexin ] could enrol 7 day follow last dose ) ; 13. parents/legal guardian plan leave area study center end study period ; 14. condition , opinion investigator , might interfere evaluation study objective .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>12 Months</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>meningitis</keyword>
	<keyword>child</keyword>
	<keyword>vaccine</keyword>
</DOC>